ClinicalTrials.gg
RecruitingNCT07483307Updated Jun 4, 2026

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer

A Phase 2 interventional study of Neoadjuvant endocrine therapy in Breast Cancer, HER2-negative Breast Cancer and HER2 Negative Breast Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Primary conditionCarcinoma, LobularRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Lobular
Why
  1. The study's title name Carcinoma, Lobular, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
176
Allocation
Not applicable
Ages
50 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 48 studies in Carcinoma, Lobular with a site in United States — 12 open to participants now, 19 under way, 2 of them phase 3. Carcinoma, Lobular · United States.

Planned enrollment
10th of 38
176 · median 35
Started
2026
with 2 others
Phase 2
16 of 48
4 open now
Primary completion
2030-03
later than 15 of 18 live
Registered
47th of 48
by date
Lead sponsor
4 of 48
Memorial Sloan Kettering Cancer Center

Among the 48 studies in Carcinoma, Lobular with a site in United States, this one is the 10th largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2026, is one of 16 in phase 2, reaches primary completion later than 15 of the 18 other live ones, and was the 47th registered.

Carcinoma, Lobular

69 studies on the registry are indexed under Carcinoma, Lobular; 18 are open to participants now.

Browse Carcinoma, Lobular studies →

Open to participants now

12 of the 48 studies in Carcinoma, Lobular with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Carcinoma, Lobular studies recruiting now, 12 (80%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 50 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Carcinoma, Lobular with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to look at how effective neoadjuvant (before surgery) endocrine therapy (NET) is in participants with invasive lobular carcinoma (ILC) who have breast-conserving surgery (BCS). The main purpose of the study is to see if NET reduces the chance of having cancer cells at the edges of tissue removed during surgery (positive margins).

03

Conditions studied

  • Breast Cancer
  • HER2-negative Breast Cancer
  • HER2 Negative Breast Carcinoma
  • ER+ Breast Cancer
  • Lobular Breast Carcinoma

Browse trials for

Keywords

  • Breast Cancer
  • HER2-negative Breast Cancer
  • HER2 Negative Breast Carcinoma
  • ER+ Breast Cancer
  • 26-095
  • Memorial Sloan Kettering Cancer Center
  • Lobular Breast Cancer
04

In context

Carcinoma, Lobular Reclassified

69 studies on the registry are indexed under Carcinoma, Lobular; 18 are open to participants now.

This study's planned enrollment of 176 is above the median of 59 across 49 interventional studies indexed under Carcinoma, Lobular.

Browse Carcinoma, Lobular studies →

Lead sponsor

Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.

Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.

Compared within Carcinoma, Lobular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written by participant or legally authorized representative
  • women aged ≥50 years with -proven cT2-T3 N0-1 ILC who opt to undergo and are medically fit to undergo BCS at enrollment.
  • Tumors of the ER+/- subtype, defined as:

    1. ER+: Positive for ER staining as indicated by ≥10% immunoreactive tumor nuclei.
    2. HER2-: Immunohistochemistry assay demonstrating no or faint staining in ≤10% of tumor cells (IHC 0 or 1+) or negative by dual probe in situ hybridization assay.

Exclusion criteria

Exclusion Criteria:

  • Patients with prior ipsilateral breast cancer.
  • Patients with advanced regional disease (cN2/cN3) or stage 4 disease.
  • Patients who would benefit from chemotherapy, per the treating medical oncologist.
  • Patients who are not candidates for definitive breast surgery (inoperable or stage 4 disease).
  • Patients with gadolinium allergy, precluding the use of breast MRI.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
176 participants (estimated)

Study arms

  • Experimental
    Participants with ER+/HER2- Breast Cancer

    Participants will be postmenopausal women aged ≥50 years with biopsy-proven cT2-T3 N0-1 ILC, ER+/HER2- subtype

    Drug: Neoadjuvant endocrine therapy

Interventions

  • DrugNeoadjuvant endocrine therapy

    The endocrine therapy used for the NET in this study will be anastrozole, letrozole, exemestane, or tamoxifen.

    Also known as: NET

This study also gives AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., ExemestaneStudies of ExemestaneExemestane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

07

What researchers measure

Primary outcomes

  1. Rate of positive surgical margins after breast cancer surgery

    To prospectively evaluate rates of positive surgical margins after initial breast cancer surgery/BCS among postmenopausal women with cT2-3 N0-1 ER+/HER2- ILC who have undergone a course of NET.

    Time frame: up to 3 months

08

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Anita Mamtani, MD · Contact646-888-6864
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Anita Mamtani, MD · Contact646-888-6864
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Anita Mamtani, MD · Contact646-888-6864
  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Anita Mamtani, MD · Contact646-888-6864
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • Anita Mamtani, MD · Contact646-888-6864
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Anita Mamtani, MD · Contact646-888-6864
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
    Uniondale, New York 11553, United States
    Recruiting
    • Anita Mamtani, MD · Contact646-888-6864
09

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Mar 2030, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 19, 2026
StartActual
Mar 13, 2026
Primary completionEst.
Mar 13, 2030
CompletionEst.
Mar 13, 2030
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07483307
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Mar 13, 2026
Primary completion
Mar 13, 2030 (estimated)
Completion
Mar 13, 2030 (estimated)
Last update
Jun 4, 2026

Study contacts

Anita Mamtani, MD
Contact
mamtana1@mskcc.org
646-888-6864
George Plitas, MD
Contact
PlitasG@mskcc.org
646-888-5368
Anita SKCCSC(P Mamtani, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anastrozole · Exemestane

Start the discussion